ruboxistaurin has been researched along with Diabetic Nephropathies in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 25 (89.29) | 29.6817 |
| 2010's | 3 (10.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alicic, RZ; Tuttle, KR | 1 |
| Cazenave, M; Gauthier, M; Gueutin, V; Izzedine, H | 1 |
| Ahmed, RM; Al-Amin, MA; Al-Onazi, AS; Al-Rasheed, NM; Attia, HA; Poizat, C | 1 |
| Cherney, DZ; Diamandis, EP; Konvalinka, A; Lai, V; Lorraine, J; Miller, JA; Reich, H; Scholey, JW; Soosaipillai, A; Zinman, B | 1 |
| Gao, B; Gilbert, RE; Ingram, AJ; Kelly, DJ; Krepinsky, JC; Peng, F; Wu, D; Zhang, B | 1 |
| Haller, H; Meier, M; Menne, J | 1 |
| Bakris, GL; Burney, BO; Kalaitzidis, RG | 1 |
| Inoguchi, T; Umeda, F | 1 |
| Gilbert, RE; Gow, RM; Hepper, C; Jaworski, K; Kelly, DJ; Kemp, BE; Wilkinson-Berka, JL; Zhang, Y | 1 |
| Anderson, PW; Tuttle, KR | 1 |
| Araki, S; Haneda, M; Isono, M; Kashiwagi, A; Kitada, M; Koya, D; Sugimoto, T | 1 |
| Tuttle, KR; Williams, ME | 1 |
| Chanty, A; Gilbert, RE; Gow, RM; Kelly, DJ; Zhang, Y | 1 |
| Tuttle, KR | 1 |
| Bearelly, S; Cooney, MJ; Dar, M; Goebel, JA; Joy, SV; Scates, AC; Taulien, CA | 1 |
| Bastyr, EJ; Bril, V; Kempler, P; Litchy, WJ; Price, KL; Tesfaye, S; Vinik, AI | 1 |
| Anderson, PW; Bakris, GL; Hu, K; McGill, JB; Toto, RD; Tuttle, KR | 1 |
| Joy, SV; Taulien, CA | 1 |
| Andrassy, M; Fujita, T; Harja, E; Schmidt, AM; Yan, SF | 1 |
| Williams, ME | 1 |
| Anderson, PW; Bakris, GL; Gilbert, RE; Haney, DJ; Kelly, DJ; Kim, SA; McGill, JB; Toto, RD; Tuttle, KR | 1 |
| Anderson, PW; McGill, JB; Tuttle, KR | 1 |
| Anderson, PW; Haney, DJ; Lin, TE; McGill, JB; Tuttle, KR | 1 |
| Fantus, IG; Frecker, H; Goldberg, HJ; Munk, S; Wang, H; Whiteside, CI; Xia, L | 1 |
| Shah, SV; Swaminathan, S | 1 |
| Haneda, M; Isshiki, K; Kashiwagi, A; Kikkawa, R; King, GL; Koya, D; Maeda, S; Nakagawa, H; Sato, H; Sugimoto, T; Ways, DK; Yasuda, H | 1 |
14 review(s) available for ruboxistaurin and Diabetic Nephropathies
| Article | Year |
|---|---|
Novel therapies for diabetic kidney disease.
Topics: Acetylcysteine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Antioxidants; Bosentan; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Endothelins; Enzyme Inhibitors; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Indoles; Janus Kinases; Maleimides; Polyamines; Protein Kinase C; Pyridones; Pyridoxamine; Sevelamer; Sulfonamides | 2014 |
[Diabetic nephropathy: emerging treatments].
Topics: Adrenocorticotropic Hormone; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antifibrinolytic Agents; Antineoplastic Agents, Hormonal; Antioxidants; Bone Density Conservation Agents; Diabetic Nephropathies; Doxycycline; Enzyme Inhibitors; Ergocalciferols; Hormones; Humans; Indoles; Maleimides; Octreotide; Pentoxifylline; Pyridones; Pyridoxamine; Silymarin; Vitamin B Complex | 2014 |
Targeting the protein kinase C family in the diabetic kidney: lessons from analysis of mutant mice.
Topics: Animals; Diabetic Nephropathies; Diabetic Neuropathies; Enzyme Activation; Enzyme Inhibitors; Humans; Hyperglycemia; Indoles; Isoenzymes; Kidney; Maleimides; Mice; Mice, Knockout; Mice, Mutant Strains; Mice, Transgenic; Models, Animal; Protein Kinase C; Protein Kinase C beta; Risk Factors | 2009 |
Novel therapies of diabetic nephropathy.
Topics: Amides; Animals; Diabetic Nephropathies; Fumarates; Humans; Indoles; Maleimides; Pyridoxamine; Superoxides | 2009 |
[Role of PKC in the pathogenesis of diabetic vascular complications].
Topics: Animals; Clinical Trials as Topic; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Enzyme Inhibitors; Humans; Indoles; Isoenzymes; Maleimides; Protein Kinase C; Protein Kinase C beta; Risk Factors | 2002 |
A novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C beta inhibition.
Topics: Animals; Animals, Genetically Modified; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Diabetic Nephropathies; Drug Evaluation, Preclinical; Endothelium, Vascular; Enzyme Inhibitors; Female; Humans; Indoles; Kidney Failure, Chronic; Male; Maleimides; Mice; Mice, Mutant Strains; Protein Kinase C; Protein Kinase C beta; Rats; Rats, Sprague-Dawley; Receptors, Cell Surface; Receptors, Leptin; Renin | 2003 |
The next generation of diabetic nephropathy therapies: an update.
Topics: Animals; Diabetic Nephropathies; Disease Progression; Enzyme Inhibitors; Glycation End Products, Advanced; Glycosaminoglycans; Humans; Indoles; Maleimides; Models, Animal; Protein Kinase C; Pyridoxamine; Renal Agents; Thiazoles | 2005 |
Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications.
Topics: Animals; Clinical Trials as Topic; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Neuropathies; Enzyme Inhibitors; Humans; Indoles; Maleimides; MEDLINE; Protein Kinase C; Protein Kinase C beta; Treatment Outcome | 2005 |
Ruboxistaurin.
Topics: Animals; Clinical Trials as Topic; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Enzyme Inhibitors; Humans; Indoles; Maleimides; Protein Kinase C | 2006 |
Protein kinase C beta/early growth response-1 pathway: a key player in ischemia, atherosclerosis, and restenosis.
Topics: Animals; Coronary Artery Disease; Coronary Restenosis; Diabetic Angiopathies; Diabetic Nephropathies; Disease Models, Animal; Early Growth Response Protein 1; Endothelium, Vascular; Humans; Indoles; Maleimides; Mice; Mitogen-Activated Protein Kinase Kinases; Myocardial Ischemia; Oxidative Stress; Phosphorylation; Protein Kinase C; Protein Kinase C beta; Signal Transduction; Tunica Intima; Up-Regulation | 2006 |
New potential agents in treating diabetic kidney disease: the fourth act.
Topics: Animals; Diabetic Nephropathies; Drugs, Investigational; Glycation End Products, Advanced; Glycosaminoglycans; Humans; Indoles; Maleimides; Protein Kinase C; Protein Kinase Inhibitors; Pyridoxamine; Renal Agents; Treatment Outcome | 2006 |
Ruboxistaurin: LY 333531.
Topics: Animals; Clinical Trials as Topic; Diabetes Complications; Diabetic Nephropathies; Diabetic Retinopathy; Drugs, Investigational; Humans; Indoles; Maleimides; Protein Kinase C; Rats | 2007 |
Protein kinase C beta inhibition: the promise for treatment of diabetic nephropathy.
Topics: Animals; Clinical Trials as Topic; Diabetic Nephropathies; Glomerular Filtration Rate; Humans; Indoles; Maleimides; Models, Chemical; Protein Kinase C; Protein Kinase C beta; Treatment Outcome | 2007 |
Novel approaches targeted toward oxidative stress for the treatment of chronic kidney disease.
Topics: Biomarkers; Chronic Disease; Diabetic Nephropathies; Disease Progression; Drugs, Investigational; Glycation End Products, Advanced; Humans; Indoles; Iron; Kidney; Kidney Diseases; Maleimides; Oxidative Stress; Protein Kinase C; Protein Kinase Inhibitors; Pyridoxamine; Reactive Oxygen Species; Treatment Outcome; Vitamin B Complex | 2008 |
4 trial(s) available for ruboxistaurin and Diabetic Nephropathies
| Article | Year |
|---|---|
Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial.
Topics: Adult; Diabetic Nephropathies; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Indoles; Male; Maleimides; Middle Aged; Protein Kinase C; Protein Kinase C beta | 2005 |
The effect of ruboxistaurin on nephropathy in type 2 diabetes.
Topics: Aged; Albuminuria; Black or African American; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Enzyme Inhibitors; Female; Glomerular Filtration Rate; Humans; Indoles; Male; Maleimides; Middle Aged; Pilot Projects; Time Factors; United States; White People | 2005 |
Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes.
Topics: Adult; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Enzyme Inhibitors; Humans; Indoles; Maleimides; Middle Aged; Placebos; Protein Kinase C; Protein Kinase C beta; Transforming Growth Factor beta | 2007 |
Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease.
Topics: Diabetic Nephropathies; Diabetic Retinopathy; Double-Blind Method; Female; Humans; Indoles; Kidney; Male; Maleimides; Middle Aged; Protein Kinase C; Time Factors | 2007 |
10 other study(ies) available for ruboxistaurin and Diabetic Nephropathies
| Article | Year |
|---|---|
Ruboxistaurin attenuates diabetic nephropathy via modulation of TGF-β1/Smad and GRAP pathways.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; GRB2 Adaptor Protein; Indoles; Kidney Function Tests; Male; Maleimides; Protein Kinase C beta; Rats, Wistar; Signal Transduction; Smad2 Protein; Smad3 Protein; Transforming Growth Factor beta1 | 2016 |
Effect of protein kinase Cbeta inhibition on renal hemodynamic function and urinary biomarkers in humans with type 1 diabetes: a pilot study.
Topics: Albuminuria; Blood Pressure; Chemokine CCL2; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Enzyme Inhibitors; Epidermal Growth Factor; Glomerular Filtration Rate; Hemodynamics; Humans; Indoles; Kidney; Maleimides; Protein Kinase C; Protein Kinase C beta | 2009 |
PKC-beta1 mediates glucose-induced Akt activation and TGF-beta1 upregulation in mesangial cells.
Topics: Animals; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Enzyme Activation; ErbB Receptors; Female; Glucose; Indoles; Kidney; Maleimides; Mesangial Cells; Models, Biological; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase C; Protein Kinase C beta; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Rats; Recombinant Proteins; Signal Transduction; Transcription Factor AP-1; Transcriptional Activation; Transforming Growth Factor beta1; Up-Regulation | 2009 |
Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension.
Topics: Albuminuria; Animals; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Diabetic Nephropathies; Disease Progression; Enzyme Inhibitors; Female; Hypertension; Immunohistochemistry; Indoles; Kidney; Kidney Glomerulus; Maleimides; Organ Size; Protein Kinase C; Protein Kinase C beta; Rats; Rats, Mutant Strains; Reference Values | 2003 |
Translocation of glomerular p47phox and p67phox by protein kinase C-beta activation is required for oxidative stress in diabetic nephropathy.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Biological Transport; Deoxyguanosine; Diabetic Nephropathies; Enzyme Activation; Enzyme Inhibitors; Indoles; Isoenzymes; Kidney Glomerulus; Male; Maleimides; Membranes; NADPH Oxidases; Oxidative Stress; Phosphoproteins; Protein Kinase C; Protein Kinase C beta; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; RNA, Messenger; Staining and Labeling | 2003 |
Molecule of the month. Ruboxistaurin mesilate hydrate.
Topics: Clinical Trials, Phase II as Topic; Diabetes Complications; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Enzyme Inhibitors; Humans; Indoles; Maleimides | 2003 |
Protein kinase Cbeta inhibition attenuates osteopontin expression, macrophage recruitment, and tubulointerstitial injury in advanced experimental diabetic nephropathy.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Enzyme Inhibitors; Female; Indoles; Kidney; Macrophage Activation; Maleimides; Nephritis, Interstitial; Osteopontin; Protein Kinase C; Protein Kinase C beta; Rats; Sialoglycoproteins; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2005 |
Linking metabolism and immunology: diabetic nephropathy is an inflammatory disease.
Topics: Animals; Diabetic Nephropathies; Enzyme Inhibitors; Humans; Indoles; Intercellular Adhesion Molecule-1; Kidney; Maleimides; Mice; Models, Animal; Protein Kinase C; Protein Kinase C beta; Rats | 2005 |
Reactive oxygen species, PKC-beta1, and PKC-zeta mediate high-glucose-induced vascular endothelial growth factor expression in mesangial cells.
Topics: Animals; Cyclic N-Oxides; Diabetic Nephropathies; Fluorescent Antibody Technique; Glucose; Indoles; Maleimides; Mesangial Cells; Molecular Chaperones; NADPH Oxidases; Oligodeoxyribonucleotides, Antisense; Protein Kinase C; Protein Kinase C beta; Protein Kinase Inhibitors; Rats; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Spin Labels; Vascular Endothelial Growth Factor A | 2007 |
Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes.
Topics: Albuminuria; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Enzyme Inhibitors; Gene Expression Regulation; Glomerular Mesangium; Indoles; Isoenzymes; Kidney Glomerulus; Male; Maleimides; Mice; Mice, Mutant Strains; Protein Kinase C; Protein Kinase C beta; Rats; Transforming Growth Factor beta | 2000 |